Baird Medical Investment Holdings Limited
NASDAQ:BDMDMedical - Devices
-$0.09 today
- Market cap
- $50.65M
- Beta
- -1.23
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.94
Volume 0.02M
Average 0.37M
BDMD Net Income
Bottom-line profit after all expenses, interest, and taxes.
Baird Medical Investment Holdings LimitedNASDAQ: BDMD
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income turns negative
Q4 FY2025 net income was -$15.98M, compared with $8.12M a year earlier.
Context
- Net income amounted to 121.0% of revenue in FY2025, up 87.4 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Net Income history
USD · from the income statement
- Latest · FY2025
- (27.28M) USD
- Year-over-year change
- -319.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.28M) | -319.0% |
| FY2024 | 2024-12-31 | 12.45M | +18.1% |
| FY2023 | 2023-12-31 | 10.55M | -16.1% |
| FY2022 | 2022-12-31 | 12.57M | +7.6% |
| FY2021 | 2021-12-31 | 11.68M | — |
Net Income vs competitors
How BDMD compares with its peers on the latest reported figures
- BDMD's FY2025 net income of -$27.28M is the 2nd highest of the 4 companies compared; the peer median is -$31.96M.
- Its year-over-year change of -319.0% is the lowest of 4, against a peer median of +14.8%.
- Net income amounts to 121.0% of revenue for BDMD, versus a peer median of 38.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$15.38M | -25.7% | — | 44.1% | |
BDMDBaird Medical Investment Holdings Limited | FY2025 | -$27.28M | -319.0% | — | 121.0% |
| LTM Mar 2026 | -$31.96M | +20.9% | — | 33.3% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | -$58.75M | +14.8% | — | — |
| Peer median (excluding BDMD) | -$31.96M | +14.8% | — | 38.7% | |
Competitors are the stored peer set for BDMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.72M | 35.09M | 31.46M | 37.04M | 22.54M |
| Cost of Revenue | 4.54M | 7.05M | 4.23M | 4.38M | 3.65M |
| Gross Profit | 23.18M | 28.04M | 27.23M | 32.65M | 18.88M |
| Gross Margin | 83.6% | 79.9% | 86.6% | 88.2% | 83.8% |
| Research & Development | 1.04M | 3.86M | 4.27M | 6.17M | 20.13M |
| Selling, General & Admin | 10.22M | 10.55M | 11.09M | 9.96M | 24.38M |
| Operating Expenses | 9.76M | 13.03M | 15.37M | 17.34M | 44.42M |
| Depreciation & Amortization | 1.4M | 1.47M | 1.01M | 1.51M | 1.1M |
| EBITDA | 14.16M | 16.29M | 12.88M | 16.17M | (24.53M) |
| EBITDA Margin | 51.1% | 46.4% | 40.9% | 43.7% | -108.9% |
| Operating Income | 11.92M | 13.63M | 11.86M | 15.32M | (25.54M) |
| Operating Margin | 43.0% | 38.8% | 37.7% | 41.4% | -113.3% |
| Interest Income | 2.33K | 8.55K | 0 | 393 | 0 |
| Interest Expense | 153.92K | 299.27K | 284.27K | 576.75K | 737.37K |
| Other Income / Expenses | 688.35K | 890.15K | 497.48K | (1.23M) | (837.57K) |
| Income Before Tax | 12.61M | 14.52M | 12.36M | 14.09M | (26.37M) |
| Pre-Tax Margin | 45.5% | 41.4% | 39.3% | 38.0% | -117.0% |
| Income Tax Expense | 2.42M | 1.75M | 1.7M | 1.49M | 1.17M |
| Net Income | 11.68M | 12.57M | 10.55M | 12.45M | (27.28M) |
| Net Margin | 42.1% | 35.8% | 33.5% | 33.6% | -121.0% |
| EPS (Basic) | (0.02) | 0.02 | 0.41 | 0.49 | (0.98) |
| EPS (Diluted) | (0.02) | 0.02 | 0.41 | 0.49 | (0.98) |
| Weighted Avg Shares | 7.19M | 6.29M | 7.58M | 25.56M | 27.79M |
| Weighted Avg Shares (Diluted) | 7.19M | 7.19M | 7.58M | 25.63M | 27.79M |
Baird Medical Investment Holdings Limited
NASDAQ:BDMD
Intrinsic Alpha fair value
Locked
Current Price
$1.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.